ronapreve
roche registration gmbh - casirivimab, imdevimab - covid-19 virus infection - immune sera og immunoglobuliner, - ronapreve is indicated for:treatment of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19 (see section 4. prevention of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg (see section 4. the use of ronapreve should take into account information on the activity of ronapreve against viral variants of concern. se afsnit 4. 4 og 5.
gavreto
roche registration gmbh - pralsetinib - carcinom, ikke-småcellet lunge - antineoplastiske midler - gavreto is indicated as monotherapy for the treatment of adult patients with rearranged during transfection (ret) fusion-positive advanced non-small cell lung cancer (nsclc) not previously treated with a ret inhibitor.
lunsumio
roche registration gmbh - mosunetuzumab - lymfom, follikulært - antineoplastic agents, monoclonal antibodies - lunsumio as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (fl) who have received at least two prior systemic therapies.
vabysmo
roche registration gmbh - faricimab - wet macular degeneration; macular edema; diabetes complications - oftalmologiske - vabysmo is indicated for the treatment of adult patients with:neovascular (wet) age-related macular degeneration (namd),visual impairment due to diabetic macular oedema (dme).
columvi
roche registration gmbh - glofitamab - lymphoma, large b-cell, diffuse - antineoplastiske midler - columvi as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl), after two or more lines of systemic therapy.
xenical
cheplapharm arzneimittel gmbh - orlistat - fedme - antiobesity preparations, excl. diætprodukter - xenical er angivet sammen med et mildt hypokalorisk kost til behandling af overvægtige patienter med en body mass index (bmi) større eller lig med 30 kg/m2, eller overvægtige patienter (bmi > 28 kg/m2) med tilhørende risikofaktorer. behandling med orlistat bør seponeres efter 12 uger, hvis patienterne ikke har været i stand til at tabe mindst 5% af kroppens vægt, målt ved start af behandling.
bcp 203 h flydende middel
fmc europe nv, agrochemical products group - linuron, clomazon - flydende middel - 250 g/l linuron; 45 g/l clomazon
minimet minigranulat
rotam agrochemical europe limited - metsulfuron-methyl, metsulfuron - minigranulat - 200 g/kg metsulfuron-methyl ; (~ 193 g/kg metsulfuron
ergon vanddispergerbart granulat
rotam agrochemical europe limited - thifensulfuron-methyl, thifensulfuron, metsulfuron-methyl, metsulfuron - vanddispergerbart granulat - 682 g/kg thifensulfuron-methyl ; (~ 657 g/kg thifensulfuron ; 68 g/kg metsulfuron-methyl ; (~ 65,5 g/kg metsulfuron
nautius vanddispergerbart granulat
rotam agrochemical europe limited - tribenuron-methyl, tribenuron, thifensulfuron-methyl, thifensulfuron - vanddispergerbart granulat - 150 g/kg tribenuron-methyl ; (~ 145 g/kg tribenuron ; 400 g/kg thifensulfuron-methyl ; (~ 386 g/kg thifensulfuron